SPECIALTY TOPICS · GUIDE
Growth Hormone and IGF-1 in Aging Research
What small trials, a systematic review, FDA label and import alert say about growth hormone and IGF-1 in healthy older adults, and why animal and genetic findings do not settle the question.
Content last updated . This page has not been medically reviewed.
Back to Longevity & Healthy AgingEvidence labels used here. Approved medicine means a regulator has approved a named use. Mixed means studies disagree or measure different things. Insufficient evidence means too little to judge. Preclinical means cells or animals only. Evidence of harm means trials or labels report real adverse effects. Marketing claim means a statement not backed by the sources read.
What small trials in older adults found
- The 1990 study that started the interest. Twenty-one healthy men aged 61 to 81 with low IGF-1 were followed for six months; 12 received GH injections and 9 did not. The treated men had more lean mass, less fat mass and slightly higher lumbar spine bone density than the untreated men. [3] It was small, and it measured body composition, not illness, falls or survival.
- A 2002 randomized trial. One hundred thirty-one healthy people aged 65 to 88 were given GH, sex steroids, both, or placebo for 26 weeks. GH raised lean mass and lowered fat mass. Strength gains were marginal at best and only in some groups. Swelling, carpal tunnel symptoms and joint pain were more common with GH, and diabetes or glucose intolerance occurred in 18 GH-treated men versus 7 not receiving GH. The authors concluded GH use in older people should be confined to controlled studies. [4]
- A 2007 systematic review. Eighteen study groups were pooled. Fat mass fell by about 2 kg and lean mass rose by about 2 kg, bone density and most blood fats did not change, and the treated groups had more soft tissue swelling, joint pain, carpal tunnel syndrome and breast enlargement in men, and somewhat more diabetes. The reviewers wrote that GH could not be recommended as an anti-aging therapy. They noted most trials were small and that some outcomes were rarely measured. [5]
Label: mixed for body composition (small changes); no good evidence of benefit for longevity or healthy lifespan, since none of these studies measured those; evidence of harm for the side effects above.
IGF-1: a puzzle, not a target
Animals with low GH or IGF-1 signaling often live longer, which is why the pathway is studied. Humans do not follow that pattern simply.- Rare genetic deficiency. In a 22-year follow-up of Ecuadorian people with GH receptor deficiency, there was one non-lethal cancer and no diabetes, versus 17% cancer and 5% diabetes in comparison relatives. [6] A review of Laron syndrome (congenital IGF-1 deficiency) reports the same low cancer pattern. [7] These are observations in a rare condition, and they do not show that lowering IGF-1 in others would prevent cancer. Label: insufficient evidence for any practical use.
- Older adults in general. In 945 US adults aged 65 and older followed for a median of 11.3 years, lower IGF-1 and big swings in IGF-1 over time were each linked with higher mortality. The authors noted this contrasts with animal data. [8] This is an association; it does not show that raising IGF-1 lengthens life.
So there is no simple "more is better" or "less is better" rule, and an IGF-1 blood level is not a goal to chase. This is not test interpretation advice.
How to read the claims
A rise in lean mass is a body-composition result. It is not the same as living longer, being stronger in daily life, or having fewer illnesses. Clinics that sell GH for aging are marketing a use no regulator has approved. [2] For the research on releasing peptides see growth-hormone-releasing peptides, for how peptides and GH differ see peptides vs growth hormone, and for oral GH mimics see MK-677. For why aging is not a treatable condition under current rules see Is aging a disease?. For hormone trials with a similar profile see testosterone therapy and aging.If you take GH for a diagnosed deficiency, talk with your prescriber before changing anything. If you have had swelling, joint pain, high blood sugar or any new symptom, contact a clinician.
Frequently asked questions
Is growth hormone approved to slow aging?
No. The US label covers growth failure in children and GH deficiency in adults, and FDA says no GH use for anti-aging has been authorized. [1][2]
Did the trials show growth hormone helps older adults live longer or stay stronger?
They measured body composition over months, not lifespan. Lean mass rose and fat mass fell a little, with unclear gains in strength and more side effects. [5][4]
What side effects were seen in healthy older adults?
Swelling, joint pain, carpal tunnel symptoms and, in one trial, more diabetes or glucose intolerance in treated men. [4][5]
Does low IGF-1 mean a longer life?
Not in older adults studied so far. Lower IGF-1 was linked with higher mortality in one large cohort, though that cannot show cause. [8]
Are people with rare GH receptor deficiency evidence that lowering IGF-1 prevents cancer?
It is an intriguing observation in a very small group, not proof that it works in others. [6][7]
Where do GH-releasing peptides fit?
They are a separate group of compounds; see growth-hormone-releasing peptides for what is known.
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
What GH is approved for
Safety information from the label and FDA
References
- U.S. National Library of Medicine, DailyMed. Genotropin (somatropin) label, Pfizer, published 2026-08-06 (FDA prescribing information). Read 2026-10-22.
- U.S. Food and Drug Administration. Import Alert 66-71: Detention Without Physical Examination of Unapproved Human Growth Hormone (HGH), published 2026-04-07. Read 2026-10-22.
- Rudman D, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990;323(1):1-6. Read 2026-10-22.
- Blackman MR, et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA. 2002;288(18):2282-92. Read 2026-10-22.
- Liu H, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146(2):104-15. Read 2026-10-22.
- Guevara-Aguirre J, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med. 2011;3(70):70ra13. Read 2026-10-22.
- Laron Z, Werner H. Congenital IGF-1 deficiency protects from cancer: lessons from Laron syndrome. Endocr Relat Cancer. 2023;30(9):e220394. Read 2026-10-22.
- Sanders JL, et al. Trajectories of IGF-I predict mortality in older adults: the Cardiovascular Health Study. J Gerontol A Biol Sci Med Sci. 2018;73(7):953-959. Read 2026-10-22.